Download Files:
Ilorasertib (hydrochloride)
$80 – $1,600
Products Details
Product Description
– Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][2].
Web ID
– HY-16018A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H22ClFN6O2S
References
– [1]Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.|[2]Yi-Chun Wang, et al. Abstract 858: Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models. Cancer Res (2012) 72 (8_Supplement): 858.
CAS Number
– 1847485-91-9
Molecular Weight
– 525.00
Compound Purity
– 99.67
SMILES
– O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2.[H]Cl
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 41.67 mg/mL (ultrasonic)
Target
– Aurora Kinase;PDGFR;VEGFR
Isoform
– Aurora A;Aurora B;Aurora C;PDGFRα;PDGFRβ;VEGFR1/Flt-1;VEGFR2/KDR/Flk-1;VEGFR3/Flt-4
Pathway
– Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
